PCM
LUCD icon

Perkins Capital Management’s Lucid Diagnostics LUCD Stock Holding History

Perkins Capital Management’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.2M Sell
1,125,000
-1,000
-0.1% -$1.08K 0.91% 28
2026
Q1 		$1.29M Hold
1,126,000
– – 1.21% 22
2025
Q4 		$1.23M Sell
1,126,000
-1,000
-0.1% -$1.12K 0.97% 33
2025
Q3 		$1.14M Buy
+1,127,000
New +$1.23M 1% 33

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Perkins Capital Management's LUCD Position: Q2 2026 in Review

Perkins Capital Management reduced its Lucid Diagnostics (LUCD) stake by 0.09% in Q2 2026, selling an estimated $1.08K and leaving 1,125,000 shares worth $1.2M. The position accounts for 0.91% of the portfolio, ranked #28.

Perkins Capital Management first reported a position in LUCD in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.29M in Q1 2026. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Perkins Capital Management held 1,125,000 shares of Lucid Diagnostics worth $1.2M as of Q2 2026.
  • Perkins Capital Management sold 1,000 Lucid Diagnostics shares in Q2 2026, an estimated $1.08K.
  • Lucid Diagnostics made up 0.91% of Perkins Capital Management's portfolio in Q2 2026, its #28 holding.
  • Perkins Capital Management first reported a position in Lucid Diagnostics in Q3 2025 and has held it in 4 quarters since.
  • Perkins Capital Management's Lucid Diagnostics position peaked at $1.29M in Q1 2026.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Perkins Capital Management's 13F filing for Q2 2026, filed 24 Jul 2026.